{"DataElement":{"publicId":"4809691","version":"1","preferredName":"Waldenstrom Macroglobulinemia Chemosensitivity Type","preferredDefinition":"A description of the sensitivity of waldenstrom macroglobulinemia to chemotherapy.","longName":"4809656v1.0:4809659v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"4809656","version":"1","preferredName":"Waldenstrom Macroglobulinemia Chemosensitivity","preferredDefinition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy._Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","longName":"4809654v1.0:2954712v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"4809654","version":"1","preferredName":"Waldenstrom Macroglobulinemia","preferredDefinition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy.","longName":"C80307","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Waldenstrom Macroglobulinemia","conceptCode":"C80307","definition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"15418464-C950-940F-E050-BB89AD436363","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"ONEDATA","dateModified":"2015-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2954712","version":"1","preferredName":"Chemosensitivity","preferredDefinition":"Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","longName":"C71488","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemosensitivity","conceptCode":"C71488","definition":"Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"765EB49C-413A-F476-E040-BB89AD43561B","latestVersionIndicator":"Yes","beginDate":"2009-10-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2009-10-20","modifiedBy":"ONEDATA","dateModified":"2009-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2842596","version":"1","preferredName":"Outcome of Therapy","preferredDefinition":"The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C18919 ","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63D982FA-DFBF-58C7-E040-BB89AD433E84","latestVersionIndicator":"Yes","beginDate":"2009-02-26","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-02-26","modifiedBy":"CURTIST","dateModified":"2009-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"15418464-C95E-940F-E050-BB89AD436363","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"KUMMEROA","dateModified":"2021-04-27","changeDescription":". 2021-4-27 ak OK to release per WZ.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4809659","version":"1","preferredName":"Waldenstrom Macroglobulinemia Chemosensitivity Type","preferredDefinition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy._Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better._Something distinguishable as an identifiable class based on common qualities.","longName":"4809659v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not applicable","valueDescription":"Not applicable","ValueMeaning":{"publicId":"4809671","version":"1","preferredName":"Not applicable","longName":"4809671","preferredDefinition":"No systemic therapy prior to the preparative regimen, or systemic therapy ended greater than 6 months prior to the preparative regimen","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"154248BD-575D-88FE-E050-BB89AD435416","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"154248BD-5775-88FE-E050-BB89AD435416","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"ONEDATA","dateModified":"2015-05-04","deletedIndicator":"No"},{"value":"Resistant","valueDescription":"Resistant","ValueMeaning":{"publicId":"4809672","version":"1","preferredName":"Resistant","longName":"4809672","preferredDefinition":"Less than 50% reduction in measurable tumor cell mass, bone marrow and serum paraprotein","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"154248BD-577F-88FE-E050-BB89AD435416","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"154248BD-5797-88FE-E050-BB89AD435416","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"ONEDATA","dateModified":"2015-05-04","deletedIndicator":"No"},{"value":"Sensitive","valueDescription":"Sensitive","ValueMeaning":{"publicId":"4809673","version":"1","preferredName":"Sensitive","longName":"4809673","preferredDefinition":"Greater than or equal to 50% reduction in measurable tumor cell mass, bone marrow and serum paraprotein","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"154248BD-57A1-88FE-E050-BB89AD435416","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"154248BD-57B9-88FE-E050-BB89AD435416","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"ONEDATA","dateModified":"2015-05-04","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2565695","version":"1","preferredName":"Unknown","longName":"2565695","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CDAC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-02-26","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-26","modifiedBy":"MMADDINENI","dateModified":"2024-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"15418464-C9BB-940F-E050-BB89AD436363","beginDate":"2015-04-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"ONEDATA","dateModified":"2015-05-04","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4809658","version":"1","preferredName":"Waldenstrom Macroglobulinemia Chemosensitivity Type","preferredDefinition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy.:Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.:Something distinguishable as an identifiable class based on common qualities.","longName":"C80307:C71488:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Waldenstrom Macroglobulinemia","conceptCode":"C80307","definition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy.","evsSource":"RADLEX_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Chemosensitivity","conceptCode":"C71488","definition":"Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"15418464-C994-940F-E050-BB89AD436363","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"ONEDATA","dateModified":"2015-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"15418464-C9A5-940F-E050-BB89AD436363","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"KUMMEROA","dateModified":"2021-04-27","changeDescription":". 2021-4-27 ak OK to release per WZ.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What was the sensitivity of t","type":"Preferred Question Text","description":"What was the sensitivity of the disease to any systemic treatment(s)?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"154248BD-57C3-88FE-E050-BB89AD435416","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"KUMMEROA","dateModified":"2021-04-27","changeDescription":". 2021-4-27 ak OK to release per WZ. System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}